中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 40 Issue 9
Sep.  2024
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(9): 1725-1731

Strategies and practice of conversion therapy for hepatocellular carcinoma

DOI: 10.12449/JCH240902

  • Department of Hepatobiliary Surgery，The First Affiliated Hospital of Dalian Medical University，Dalian，Liaoning 116021，China

More Information
  • Corresponding author: TAN Guang， guangtan@dmu.edu.cn （ORCID： 0009-0009-9157-773X）
  • Published Date: 2024-09-25
    Abstract
  • Due to the insidious onset and poor prognosis of primary liver cancer， most patients are found to have unresectable primary liver cancer at initial diagnosis. In recent years， with the advent of targeted therapy， immunotherapy， and local therapy， some patients with advanced liver cancer have achieved successful conversion and undergone radical surgical resection， but at the same time， such treatment has brought many issues， such as the identification of potential population for conversion， the selection of conversion regimen， the necessity and timing of surgical resection after conversion， and the necessity and duration of adjuvant therapy after conversion surgery. This article discusses the above problems in conversion therapy for liver cancer based on the author’s own experience.

     

    • FullText(HTML)
    • References(38)
  • [1]
    ZHENG RS, CHEN R, HAN BF, et al. Cancer incidence and mortality in China, 2022[J]. Chin J Oncol, 2024, 46( 3): 221- 231. DOI: 10.3760/cma.j.cn112152-20240119-00035.

    郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46( 3): 221- 231. DOI: 10.3760/cma.j.cn112152-20240119-00035.
    [2]
    VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380( 15): 1450- 1462. DOI: 10.1056/nejmra1713263.
    [3]
    Alliance of Liver Cancer Conversion Therapy, Committee of Liver Cancer, China Anti‐Cancer Association. Chinese expert consensus on conversion and perioperative therapy of primary liver cancer(2024 edition)[J]. Chin J Dig Surg, 2024, 23( 4): 492- 513. DOI: 10.3760/cma.j.cn115610-20240228-00135.

    中国抗癌协会肝癌专业委员会转化治疗协作组. 原发性肝癌转化及围手术期治疗中国专家共识(2024版)[J]. 中华消化外科杂志, 2024, 23( 4): 492- 513. DOI: 10.3760/cma.j.cn115610-20240228-00135.
    [4]
    NAGINO M, KANAI M, MORIOKA A, et al. Portal and arterial embolization before extensive liver resection in patients with markedly poor functional reserve[J]. J Vasc Interv Radiol, 2000, 11( 8): 1063- 1068. DOI: 10.1016/s1051-0443(07)61340-2.
    [5]
    SCHWAB ME, DECKER HC, MONTO A, et al. Portal vein thrombosis after transarterial embolization for hepatocellular carcinoma[J]. JAMA Surg, 2024, 159( 3): 345- 347. DOI: 10.1001/jamasurg.2023.5909.
    [6]
    CHAN A, ZHANG WY, CHOK K, et al. ALPPS versus portal vein embolization for hepatitis-related hepatocellular carcinoma: A changing paradigm in modulation of future liver remnant before major hepatectomy[J]. Ann Surg, 2021, 273( 5): 957- 965. DOI: 10.1097/SLA.0000000000003433.
    [7]
    MATSUO K, MURAKAMI T, KAWAGUCHI D, et al. Histologic features after surgery associating liver partition and portal vein ligation for staged hepatectomy versus those after hepatectomy with portal vein embolization[J]. Surgery, 2016, 159( 5): 1289- 1298. DOI: 10.1016/j.surg.2015.12.004.
    [8]
    GUIU B, HERRERO A, PANARO F. Liver venous deprivation: A bright future for liver metastases-but what about hepatocellular carcinoma?[J]. Hepatobiliary Surg Nutr, 2021, 10( 2): 270- 272. DOI: 10.21037/hbsn-21-7.
    [9]
    CHEBARO A, BUC E, DURIN T, et al. Liver venous deprivation or associating liver partition and portal vein ligation for staged hepatectomy?: A retrospective multicentric study[J]. Ann Surg, 2021, 274( 5): 874- 880. DOI: 10.1097/SLA.0000000000005121.
    [10]
    CHAOUCH MA, MAZZOTTA A, COSTA AC DA, et al. A systematic review and meta-analysis of liver venous deprivation versus portal vein embolization before hepatectomy: Future liver volume, postoperative outcomes, and oncological safety[J]. Front Med, 2023, 10: 1334661. DOI: 10.3389/fmed.2023.1334661.
    [11]
    YANG C, ZHANG HL, ZHANG LM, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2023, 20( 4): 203- 222. DOI: 10.1038/s41575-022-00704-9.
    [12]
    QIN SK, BI F, GU SZ, et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: A randomized, open-label, parallel-controlled phase II-III trial[J]. J Clin Oncol, 2021, 39( 27): 3002- 3011. DOI: 10.1200/JCO.21.00163.
    [13]
    QIN SK, LI Q, GU SZ, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma(AHELP): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6( 7): 559- 568. DOI: 10.1016/S2468-1253(21)00109-6.
    [14]
    National Health Commission of the People’s Republic of China. Standard for diagnosis and treatment of primary liver cancer(2024 edition)[J]. J Clin Hepatol, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.

    中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.
    [15]
    FINN RS, QIN SK, IKEDA M, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382( 20): 1894- 1905. DOI: 10.1056/NEJMoa1915745.
    [16]
    KUDO M, AOKI T, UESHIMA K, et al. Achievement of complete response and drug-free status by Atezolizumab plus Bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: A multicenter proof-of-concept study[J]. Liver Cancer, 2023, 12( 4): 321- 338. DOI: 10.1159/000529574.
    [17]
    ZHU XD, HUANG C, SHEN YH, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations[J]. Liver Cancer, 2021, 10( 4): 320- 329. DOI: 10.1159/000514313.
    [18]
    GORDAN JD, KENNEDY EB, ABOU-ALFA GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update[J]. J Clin Oncol, 2024, 42( 15): 1830- 1850. DOI: 10.1200/JCO.23.02745.
    [19]
    TAKEDA H, NISHIJIMA N, NASU A, et al. Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion[J]. Hepatol Res, 2019, 49( 5): 594- 599. DOI: 10.1111/hepr.13294.
    [20]
    HIDAKA M, HARA T, SOYAMA A, et al. The outcome of conversion liver resection surgery by lenvatinib treatment: A single center experience[J]. Anticancer Res, 2022, 42( 6): 3049- 3054. DOI: 10.21873/anticanres.15791.
    [21]
    ZHU XD, HUANG C, SHEN YH, et al. Hepatectomy after conversion therapy using tyrosine kinase inhibitors plus anti-PD-1 antibody therapy for patients with unresectable hepatocellular carcinoma[J]. Ann Surg Oncol, 2023, 30( 5): 2782- 2790. DOI: 10.1245/s10434-022-12530-z.
    [22]
    LLOVET JM, KUDO M, MERLE P, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma(LEAP-002): A randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2023, 24( 12): 1399- 1410. DOI: 10.1016/S1470-2045(23)00469-2.
    [23]
    FAIVRE S, RIMASSA L, FINN RS. Molecular therapies for HCC: Looking outside the box[J]. J Hepatol, 2020, 72( 2): 342- 352. DOI: 10.1016/j.jhep.2019.09.010.
    [24]
    ZHANG B, TAO BR, LI YT, et al. Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma[J]. Eur J Intern Med, 2023, 111: 37- 46. DOI: 10.1016/j.ejim.2022.12.025.
    [25]
    FULGENZI CAM, SCHEINER B, KOROLEWICZ J, et al. Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials[J]. JHEP Rep, 2023, 5( 5): 100702. DOI: 10.1016/j.jhepr.2023.100702.
    [26]
    CELSA C, CABIBBO G, PINATO DJ, et al. Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis[J]. Liver Cancer, 2024, 13( 2): 169- 180. DOI: 10.1159/000531744.
    [27]
    KUDO M, UESHIMA K, IKEDA M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation(TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial[J]. Gut, 2020, 69( 8): 1492- 1501. DOI: 10.1136/gutjnl-2019-318934.
    [28]
    KUDO M, UESHIMA K, SAEKI I, et al. A phase 2, prospective, multicenter, single-arm trial of transarterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable intermediate-stage hepatocellular carcinoma: TACTICS-L trial[J]. Liver Cancer, 2024, 13( 1): 99- 112. DOI: 10.1159/000531377.
    [29]
    HE MK, LI QJ, ZOU RH, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: A randomized clinical trial[J]. JAMA Oncol, 2019, 5( 7): 953- 960. DOI: 10.1001/jamaoncol.2019.0250.
    [30]
    LEE WH, BYUN HK, CHOI JS, et al. Liver-directed combined radiotherapy as a bridge to curative surgery in locally advanced hepatocellular carcinoma beyond the Milan criteria[J]. Radiother Oncol, 2020, 152: 1- 7. DOI: 10.1016/j.radonc.2020.07.046.
    [31]
    CHIANG CL, CHIU KWH, CHAN KSK, et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma(START-FIT): A single-arm, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2023, 8( 2): 169- 178. DOI: 10.1016/S2468-1253(22)00339-9.
    [32]
    TAI D, LOKE K, GOGNA A, et al. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma(CA 209-678): A single arm, single centre, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6( 12): 1025- 1035. DOI: 10.1016/S2468-1253(21)00305-8.
    [33]
    LIU JF, LI Z, ZHANG WG, et al. Comprehensive treatment of trans-arterial chemoembolization plus lenvatinib followed by camrelizumab for advanced hepatocellular carcinoma patients[J]. Front Pharmacol, 2021, 12: 709060. DOI: 10.3389/fphar.2021.709060.
    [34]
    ZHANG JL, ZHANG XH, MU H, et al. Surgical conversion for initially unresectable locally advanced hepatocellular carcinoma using a triple combination of angiogenesis inhibitors, anti-PD-1 antibodies, and hepatic arterial infusion chemotherapy: A retrospective study[J]. Front Oncol, 2021, 11: 729764. DOI: 10.3389/fonc.2021.729764.
    [35]
    MA YN, JIANG XM, LIU H, et al. Conversion therapy for initially unresectable hepatocellular carcinoma: Current status and prospects[J]. Biosci Trends, 2024, 17( 6): 415- 426. DOI: 10.5582/bst.2023.01322.
    [36]
    KE Q, XIN FL, FANG HP, et al. The significance of transarterial chemo(embolization) combined with tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma in the era of systemic therapy: A systematic review[J]. Front Immunol, 2022, 13: 913464. DOI: 10.3389/fimmu.2022.913464.
    [37]
    ZHANG XY, ZHU XR, LIU C, et al. The safety and efficacy of transarterial chemoembolization(TACE)+lenvatinib+programmed cell death protein 1(PD-1) antibody of advanced unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2022, 40( 4_suppl): 453. DOI: 10.1200/jco.2022.40.4_suppl.453.
    [38]
    LI XR, LI JF, ZHANG WW, et al. Long-term efficacy of sequential surgery after immune combined with targeted therapy for initially unresectable hepatocellular carcinoma[J]. Chin J Hepatobiliary Surg, 2024, 30( 1): 9- 14. DOI: 10.3760/cma.j.cn113884-20231130-00147.

    李雪瑞, 李俊锋, 张雯雯, 等. 免疫联合靶向序贯外科根治性手术方案治疗初始不可切除肝细胞癌的远期疗效[J]. 中华肝胆外科杂志, 2024, 30( 1): 9- 14. DOI: 10.3760/cma.j.cn113884-20231130-00147
    • Relative Articles

  • Relative Articles

    [1]Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association， Chinese Society of Liver Cancer， Liver Study Group of Surgery Committee of Beijing Medical Association， et al. Expert consensus on the sequential surgery following conversion therapy based on the combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)[J]. Journal of Clinical Hepatology, 2025, 41(1): 30-40. doi: 10.3760/cma.j.cn113884-20240814-00245
    [2]Yue YANG, Siyu XU, Jue WANG, Shilin DU, Chunlei ZHANG, Haiyan SONG. Mechanism of action of cinobufotalin in inhibiting lung metastasis of hepatocellular carcinoma by regulating AKT-mediated epithelial-mesenchymal transition in a nude mouse model[J]. Journal of Clinical Hepatology, 2024, 40(9): 1840-1847. doi: 10.12449/JCH240919
    [3]Chuyue ZHANG, Jianing SHI, Mingda WANG, Han WU, Lijun SHI, Tian YANG. Advances in the application of microspheres and nanoparticles in transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(4): 816-821. doi: 10.12449/JCH240428
    [4]Jianxing LUO, Yang ZHANG, Ne XIANG, Xiaoyu HU. Efficacy and safety of microwave ablation versus hepatic resection in treatment of hepatocellular carcinoma with liver cirrhosis： A Meta-analysis[J]. Journal of Clinical Hepatology, 2024, 40(9): 1807-1815. doi: 10.12449/JCH240915
    [5]Xiaoyu YIN, Qiongcong XU. Surgical treatment of gallbladder cancer： Current status and advances[J]. Journal of Clinical Hepatology, 2024, 40(12): 2366-2370. doi: 10.12449/JCH241205
    [6]Xinyu BI, Jianqiang CAI. The therapeutic paradigm of liver surgery in the era of conversion therapy[J]. Journal of Clinical Hepatology, 2024, 40(9): 1721-1724. doi: 10.12449/JCH240901
    [7]Chaofan ZHU, Xiaodong WANG. Value of local treatment combined with systemic therapy in conversion therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1732-1737. doi: 10.12449/JCH240903
    [8]Shichun LU. Challenges and reflections on conversion therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1738-1740. doi: 10.12449/JCH240904
    [9]Jing WEN, Zhe JIA, Rong HE, Yanhua ZHANG, Hongwei ZHANG, Ke ZHANG. Risk factors for pulmonary infection after laparoscopic surgery in treatment of hepatocellular carcinoma with liver cirrhosis and portal hypertension[J]. Journal of Clinical Hepatology, 2023, 39(7): 1586-1591. doi: 10.3969/j.issn.1001-5256.2023.07.012
    [10]Tianqiang JIN, Chaoliu DAI, Feng XU. Clinical effect of simultaneous surgical resection of hepatic and pancreatic lesions versus systemic chemotherapy in treatment of resectable pancreatic cancer with liver metastasis[J]. Journal of Clinical Hepatology, 2022, 38(3): 622-628. doi: 10.3969/j.issn.1001-5256.2022.03.023
    [11]Bin XU, Meiling LI, Huichuan SUN. Perioperative immunotherapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 980-984. doi: 10.3969/j.issn.1001-5256.2022.05.002
    [12]Zhaoshuo CHEN, Kecan LIN, Jingfeng LIU. Application of three-dimensional visualization in surgical operation for primary liver cancer[J]. Journal of Clinical Hepatology, 2022, 38(3): 505-509. doi: 10.3969/j.issn.1001-5256.2022.03.003
    [13]Xin Qi, Yu XiaoYuan, Liu XingKai, Zhang Ping. Value of clinical staging and typing of hilar cholangiocarcinoma in evaluating radical resection and prognosis[J]. Journal of Clinical Hepatology, 2020, 36(2): 472-475. doi: 10.3969/j.issn.1001-5256.2020.02.053
    [14]Wang Hong, Yao XiaoXiao, Qiao ShiXing. Controversies over the extent of surgical resection for hilar cholangiocarcinoma and research advances in diagnosis and treatment[J]. Journal of Clinical Hepatology, 2020, 36(3): 704-707. doi: 10.3969/j.issn.1001-5256.2020.03.053
    [15]Yuan XiangLin. Downstaging conversion therapy for advanced primary liver cancer[J]. Journal of Clinical Hepatology, 2020, 36(2): 267-271. doi: 10.3969/j.issn.1001-5256.2020.02.005
    [16]Jiang Hua, Wang YueHua. Research advances in perioperative management of hilar cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2019, 35(7): 1644-1647. doi: 10.3969/j.issn.1001-5256.2019.07.049
    [17]Ye HaiWen, Deng Yong, Zhang LingQiang, Wang HaiJiu, Zhou Ying, Xu XiaoLei, Fan HaiNing. Influence of HBV DNA load on surgical outcome of hepatitis B-associated liver cancer[J]. Journal of Clinical Hepatology, 2018, 34(9): 1995-1998. doi: 10.3969/j.issn.1001-5256.2018.09.035
    [18]Jia WeiDong, Liu WenBin. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. Journal of Clinical Hepatology, 2015, 31(6): 859-862. doi: 10.3969/j.issn.1001-5256.2015.06.009
    [19]Ye Gang, Ma Yu, Tang ChengJia, Du ChengYou. Clinical outcomes of laparoscopic hepatectomy and open hepatectomy for hepatocellular carcinoma: A meta-analysis[J]. Journal of Clinical Hepatology, 2013, 29(3): 184-190.
    [20]Wu DeQuan, Gao Feng, Sun DongSheng, Ceng ZhaoLin, Chou GongCai, Zhang XinChen. Surgical treatment of giant primary liver cancer[J]. Journal of Clinical Hepatology, 2011, 27(4): 372-374+390.
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 1.2 %其他: 1.2 %其他: 0.2 %其他: 0.2 %San Lorenzo: 0.1 %San Lorenzo: 0.1 %Taoyuan District: 0.1 %Taoyuan District: 0.1 %Tiruchi: 0.0 %Tiruchi: 0.0 %三门峡: 1.3 %三门峡: 1.3 %上海: 1.5 %上海: 1.5 %东莞: 0.1 %东莞: 0.1 %东营: 0.5 %东营: 0.5 %中卫: 2.1 %中卫: 2.1 %临汾: 0.0 %临汾: 0.0 %临沂: 0.5 %临沂: 0.5 %乐山: 0.1 %乐山: 0.1 %亳州: 0.3 %亳州: 0.3 %佛山: 0.1 %佛山: 0.1 %佳木斯: 0.3 %佳木斯: 0.3 %保定: 0.0 %保定: 0.0 %信阳: 0.5 %信阳: 0.5 %兰州: 0.1 %兰州: 0.1 %包头: 1.9 %包头: 1.9 %北京: 1.7 %北京: 1.7 %华盛顿州: 0.0 %华盛顿州: 0.0 %南京: 0.8 %南京: 0.8 %南宁: 0.5 %南宁: 0.5 %南平: 0.3 %南平: 0.3 %南昌: 0.2 %南昌: 0.2 %南通: 0.0 %南通: 0.0 %南阳: 0.5 %南阳: 0.5 %卡纳塔克: 0.0 %卡纳塔克: 0.0 %厦门: 0.5 %厦门: 0.5 %台州: 0.0 %台州: 0.0 %合肥: 0.5 %合肥: 0.5 %吉林: 2.7 %吉林: 2.7 %呼伦贝尔: 0.1 %呼伦贝尔: 0.1 %咸宁: 0.0 %咸宁: 0.0 %咸阳: 0.0 %咸阳: 0.0 %哈尔滨: 0.2 %哈尔滨: 0.2 %哥伦布: 0.0 %哥伦布: 0.0 %唐山: 0.3 %唐山: 0.3 %商丘: 0.3 %商丘: 0.3 %嘉兴: 1.8 %嘉兴: 1.8 %大庆: 0.8 %大庆: 0.8 %大连: 0.6 %大连: 0.6 %天津: 0.9 %天津: 0.9 %太原: 0.1 %太原: 0.1 %威海: 0.1 %威海: 0.1 %宁德: 0.1 %宁德: 0.1 %宁波: 0.5 %宁波: 0.5 %安庆: 0.0 %安庆: 0.0 %安康: 0.7 %安康: 0.7 %宣城: 0.9 %宣城: 0.9 %宿迁: 0.2 %宿迁: 0.2 %山景城: 0.0 %山景城: 0.0 %常州: 0.1 %常州: 0.1 %常德: 0.1 %常德: 0.1 %广元: 0.2 %广元: 0.2 %广州: 19.5 %广州: 19.5 %廊坊: 0.7 %廊坊: 0.7 %张家口: 0.6 %张家口: 0.6 %徐州: 2.8 %徐州: 2.8 %德州: 0.1 %德州: 0.1 %德罕: 0.0 %德罕: 0.0 %惠州: 0.1 %惠州: 0.1 %成都: 0.8 %成都: 0.8 %扬州: 1.1 %扬州: 1.1 %揭阳: 0.1 %揭阳: 0.1 %新乡: 0.2 %新乡: 0.2 %无锡: 0.7 %无锡: 0.7 %日照: 0.2 %日照: 0.2 %昆明: 1.1 %昆明: 1.1 %曲靖: 0.1 %曲靖: 0.1 %朝阳: 0.2 %朝阳: 0.2 %杭州: 2.6 %杭州: 2.6 %柳州: 0.0 %柳州: 0.0 %格兰特县: 0.0 %格兰特县: 0.0 %榆林: 0.1 %榆林: 0.1 %武汉: 0.6 %武汉: 0.6 %沈阳: 1.0 %沈阳: 1.0 %沧州: 0.4 %沧州: 0.4 %泰州: 1.4 %泰州: 1.4 %洛杉矶: 0.0 %洛杉矶: 0.0 %洛阳: 0.3 %洛阳: 0.3 %济南: 0.6 %济南: 0.6 %济宁: 0.2 %济宁: 0.2 %海得拉巴: 0.0 %海得拉巴: 0.0 %淄博: 0.1 %淄博: 0.1 %淮北: 0.2 %淮北: 0.2 %淮安: 0.1 %淮安: 0.1 %深圳: 0.4 %深圳: 0.4 %温州: 0.6 %温州: 0.6 %渭南: 0.2 %渭南: 0.2 %湖州: 1.3 %湖州: 1.3 %湛江: 0.1 %湛江: 0.1 %漳州: 2.5 %漳州: 2.5 %潍坊: 0.5 %潍坊: 0.5 %潮州: 0.0 %潮州: 0.0 %烟台: 0.5 %烟台: 0.5 %焦作: 0.1 %焦作: 0.1 %牡丹江: 0.2 %牡丹江: 0.2 %玉林: 0.0 %玉林: 0.0 %盐城: 0.6 %盐城: 0.6 %盘锦: 0.9 %盘锦: 0.9 %眉山: 0.0 %眉山: 0.0 %石家庄: 0.3 %石家庄: 0.3 %福州: 0.1 %福州: 0.1 %科泽科德: 0.0 %科泽科德: 0.0 %秦皇岛: 1.9 %秦皇岛: 1.9 %绍兴: 2.0 %绍兴: 2.0 %绥化: 0.3 %绥化: 0.3 %绵阳: 0.1 %绵阳: 0.1 %肇庆: 0.1 %肇庆: 0.1 %芒廷维尤: 6.4 %芒廷维尤: 6.4 %芜湖: 0.1 %芜湖: 0.1 %芝加哥: 0.6 %芝加哥: 0.6 %苏州: 0.8 %苏州: 0.8 %荆门: 2.3 %荆门: 2.3 %莫斯科: 0.1 %莫斯科: 0.1 %莱芜: 0.1 %莱芜: 0.1 %蚌埠: 0.2 %蚌埠: 0.2 %衡水: 0.1 %衡水: 0.1 %西宁: 2.1 %西宁: 2.1 %西安: 0.3 %西安: 0.3 %诺沃克: 0.0 %诺沃克: 0.0 %贵阳: 0.0 %贵阳: 0.0 %资阳: 0.1 %资阳: 0.1 %赣州: 0.7 %赣州: 0.7 %辽阳: 0.1 %辽阳: 0.1 %运城: 0.6 %运城: 0.6 %连云港: 0.1 %连云港: 0.1 %通化: 0.0 %通化: 0.0 %邯郸: 0.1 %邯郸: 0.1 %郑州: 1.3 %郑州: 1.3 %鄂州: 0.1 %鄂州: 0.1 %重庆: 1.8 %重庆: 1.8 %金华: 0.8 %金华: 0.8 %长春: 2.6 %长春: 2.6 %长沙: 0.3 %长沙: 0.3 %长治: 0.3 %长治: 0.3 %阜阳: 0.2 %阜阳: 0.2 %青岛: 0.3 %青岛: 0.3 %首尔特别: 0.0 %首尔特别: 0.0 %驻马店: 0.1 %驻马店: 0.1 %鸡西: 0.7 %鸡西: 0.7 %黄山: 0.1 %黄山: 0.1 %黄石: 0.0 %黄石: 0.0 %齐齐哈尔: 0.3 %齐齐哈尔: 0.3 %其他其他San LorenzoTaoyuan DistrictTiruchi三门峡上海东莞东营中卫临汾临沂乐山亳州佛山佳木斯保定信阳兰州包头北京华盛顿州南京南宁南平南昌南通南阳卡纳塔克厦门台州合肥吉林呼伦贝尔咸宁咸阳哈尔滨哥伦布唐山商丘嘉兴大庆大连天津太原威海宁德宁波安庆安康宣城宿迁山景城常州常德广元广州廊坊张家口徐州德州德罕惠州成都扬州揭阳新乡无锡日照昆明曲靖朝阳杭州柳州格兰特县榆林武汉沈阳沧州泰州洛杉矶洛阳济南济宁海得拉巴淄博淮北淮安深圳温州渭南湖州湛江漳州潍坊潮州烟台焦作牡丹江玉林盐城盘锦眉山石家庄福州科泽科德秦皇岛绍兴绥化绵阳肇庆芒廷维尤芜湖芝加哥苏州荆门莫斯科莱芜蚌埠衡水西宁西安诺沃克贵阳资阳赣州辽阳运城连云港通化邯郸郑州鄂州重庆金华长春长沙长治阜阳青岛首尔特别驻马店鸡西黄山黄石齐齐哈尔

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (381) PDF downloads(100) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2784]YesterdayPV[4482]TodayIP[100]TodayPV[153]Online[51]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return